Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 55.58M
Revenue (ttm) n/a
Net Income (ttm) -678,788
Shares Out 11.12M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CVKD

Cadrenal Therapeutics is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease, or ESRD, and atrial fibrillation (irregular heartbeat), or AFib. Most approved drugs, including warfarin, the only FDA-approved Vitamin K antagonists, or VKAs, which is a prescribed drug for the treatment of thrombosis, are metabolized in the liver through a pathway known as the Cytochrome CYP450 system, or CYP450,... [Read more...]

Industry Health Care
Founded 2022
CEO Quang Pham
Employees 1
Stock Exchange NASDAQ
Ticker Symbol CVKD
Full Company Profile


Cadrenal Therapeutics IPO Registration Document (S-1)

Cadrenal Therapeutics has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC